Interleukin-6 receptor inhibition modulates the immune reaction and restores titin phosphorylation in experimental myocarditis

Basic Research in Cardiology

Volumn 109, Issue 6, 2014, Pages

  Savvatis, Konstantinos ^a   Müller, Irene ^a,f   Fröhlich, Matthias ^a   Pappritz, Kathleen ^a   Zietsch, Christin ^a   Hamdani, Nazha ^e   Grote, Karsten ^b   Schieffer, Bernhard ^c   Klingel, Karin ^d   Van Linthout, Sophie ^a   Linke, Wolfgang A ^e   Schultheiss, Heinz Peter ^a   Tschöpe, Carsten ^a,f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiac inflammation; Interleukin 6; Myocarditis; Remodeling; Titin

Indexed keywords

CONNECTIN; INTERLEUKIN 6 RECEPTOR; MR 16-1; PROTEIN INHIBITOR; TOCILIZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIASTOLE; DOWN REGULATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLE; VIRUS LOAD; VIRUS MYOCARDITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; IMMUNOLOGY; METABOLISM; MYOCARDITIS; PHOSPHORYLATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONNECTIN; MALE; MICE; MICE, INBRED C57BL; MYOCARDITIS; PHOSPHORYLATION; RECEPTORS, INTERLEUKIN-6;

EID: 84911906640     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0449-2     Document Type: Article

References (48)

1. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM (2011) Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124:2882–2891. doi:10.1161/CIRCULATIONAHA.111.048520
2. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. doi:10.1016/j.pharmthera.2008.08.002
3. Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38:399–403. doi:10.1161/01.HYP.38.3.399
4. Choy E (2009) RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nat Clin Pract Rheumatol 5:66–67. doi:10.1038/ncprheum0984
5. Esfandiarei M, McManus BM (2008) Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol 3:127–155. doi:10.1146/annurev.pathmechdis.3.121806.151534
6. Fairweather D, Rose NR (2005) Inflammatory heart disease: a role for cytokines. Lupus 14:646–651. doi:10.1191/0961203305lu2192oa
7. Fairweather D, Stafford KA, Sung YK (2012) Update on coxsackievirus B3 myocarditis. Curr Opin Rheumatol 24:401–407. doi:10.1097/BOR.0b013e328353372d
8. Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK (2004) Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes 53:1643–1648. doi:10.2337/diabetes.53.7.1643
9. Fischer P, Hilfiker-Kleiner D (2007) Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 102:393–411. doi:10.1007/s00395-007-0658-z
10. Gallucci RM, Lee EG, Tomasek JJ (2006) IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice. J Invest Dermatol 126:561–568. doi:10.1038/sj.jid.5700109
11. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20. doi:10.1042/BJ20030407
12. Heymans S (2006) Inflammation and cardiac remodeling during viral myocarditis. Ernst Schering Res Found Workshop, pp 197–218
13. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, Drexler H, Filippatos G, Felix SB, Gullestad L, Hilfiker-Kleiner D, Janssens S, Latini R, Neubauer G, Paulus WJ, Pieske B, Ponikowski P, Schroen B, Schultheiss HP, Tschope C, Van Bilsen M, Zannad F, McMurray J, Shah AM (2009) Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11:119–129. doi:10.1093/eurjhf/hfn043
14. Hirota H, Yoshida K, Kishimoto T, Taga T (1995) Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92:4862–4866
15. Jaber WA, Maniu C, Krysiak J, Shapiro BP, Meyer DM, Linke WA, Redfield MM (2008) Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insight. Circ Heart Fail 1:192–199. doi:10.1161/CIRCHEARTFAILURE.108.768465
16. Jones SA, Scheller J, Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121:3375–3383. doi:10.1172/JCI57158
17. Kanda T, Takahashi T (2004) Interleukin-6 and cardiovascular diseases. Jpn Heart J 45:183–193. doi:10.1536/jhj.45.183
18. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:304–311. doi:10.1006/cyto.2002.2012
19. Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295–314. doi:10.1016/j.pharmthera.2010.05.002
20. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R (1992) Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci USA 89:314–318
21. Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427. doi:10.1210/en.2004-1468
22. Kruger M, Linke WA (2009) Titin-based mechanical signalling in normal and failing myocardium. J Mol Cell Cardiol 46:490–498. doi:10.1016/j.yjmcc.2009.01.004
23. Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, Manhiani M, Imig JD, Brands MW (2006) Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290:H935–H940. doi:10.1152/ajpheart.00708.2005
24. Linke WA, Hamdani N (2014) Gigantic business: titin properties and function through thick and thin. Circ Res 114:1052–1068. doi:10.1161/CIRCRESAHA.114.301286
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. doi:10.1006/meth.2001.1262
26. McKenzie BS, Kastelein RA, Cua DJ (2006) Understanding the IL-23-IL-17 immune pathway. Trends Immunol 27:17–23. doi:10.1016/j.it.2005.10.003
27. Nagahama KY, Togo S, Holz O, Magnussen H, Liu X, Seyama K, Takahashi K, Rennard SI (2013) Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol 49:582–591. doi:10.1165/rcmb.2012-0460OC
28. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, Williams AS, Bryant-Greenwood G, Jones SA (2006) Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 54:2084–2095. doi:10.1002/art.21942
29. Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M (2002) Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett 84:231–240. doi:10.1016/S0165-2478(02)00202-X
30. Pal M, Febbraio MA, Whitham M (2014) From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol 92:331–339. doi:10.1038/icb.2014.16
31. Poffenberger MC, Horwitz MS (2009) IL-6 during viral-induced chronic autoimmune myocarditis. Ann NY Acad Sci 1173:318–325. doi:10.1111/j.1749-6632.2009.04850.x
32. Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dorner T, Tony HP (2011) In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 63:1255–1264. doi:10.1002/art.30242
33. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y (2008) Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146. doi:10.1161/CIRCULATIONAHA.107.187998
34. Sarkar S, Vellaichamy E, Young D, Sen S (2004) Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am J Physiol Heart Circ Physiol 287:H107–H117. doi:10.1152/ajpheart.00763.2003
35. Savvatis K, Pappritz K, Becher PM, Lindner D, Zietsch C, Volk HD, Westermann D, Schultheiss HP, Tschope C (2014) Interleukin-23 deficiency leads to impaired wound healing and adverse prognosis after myocardial infarction. Circ Heart Fail 7:161–171. doi:10.1161/CIRCHEARTFAILURE.113.000604
36. Savvatis K, van Linthout S, Miteva K, Pappritz K, Westermann D, Schefold JC, Fusch G, Weithauser A, Rauch U, Becher PM, Klingel K, Ringe J, Kurtz A, Schultheiss HP, Tschope C (2012) Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis. PLoS ONE 7:e41047. doi:10.1371/journal.pone.0041047
37. Siwik DA, Chang DL, Colucci WS (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86:1259–1265. doi:10.1161/01.RES.86.12.1259
38. Tanaka T, Kanda T, McManus BM, Kanai H, Akiyama H, Sekiguchi K, Yokoyama T, Kurabayashi M (2001) Overexpression of interleukin-6 aggravates viral myocarditis: impaired increase in tumor necrosis factor-alpha. J Mol Cell Cardiol 33:1627–1635. doi:10.1006/jmcc.2001.1428
39. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M (1998) Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 31:391–398. doi:10.1016/S0735-1097(97)00494-4
40. van Nieuwenhoven FA, Turner NA (2013) The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 58:182–188. doi:10.1016/j.vph.2012.07.003
41. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24:179–189. doi:10.1016/j.immuni.2006.01.001
42. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C (2011) Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4:44–52. doi:10.1161/CIRCHEARTFAILURE.109.931451
43. Westermann D, Savvatis K, Schultheiss HP, Tschope C (2010) Immunomodulation and matrix metalloproteinases in viral myocarditis. J Mol Cell Cardiol 48:468–473. doi:10.1016/j.yjmcc.2009.08.019
44. Westermann D, Walther T, Savvatis K, Escher F, Sobirey M, Riad A, Bader M, Schultheiss HP, Tschope C (2009) Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58:1373–1381. doi:10.2337/db08-0329
45. Woodruff JF (1980) Viral myocarditis. A review. Am J Pathol 101:425–484
46. Yajima T, Knowlton KU (2009) Viral myocarditis: from the perspective of the virus. Circulation 119:2615–2624. doi:10.1161/CIRCULATIONAHA.108.766022
47. Yang F, Wu WF, Yan YL, Pang Y, Kong Q, Huang YL (2011) Expression of IL-23/Th17 pathway in a murine model of Coxsackie virus B3-induced viral myocarditis. Virol J 8:301. doi:10.1186/1743-422X-8-301
48. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Cheng X, Liao YH (2010) Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol 185:4004–4010. doi:10.4049/jimmunol.1001718